Roundup: Singaporean health workers get free access to Intellect’s self-care app, Terumo signs partnership to expand predictive analytics, and more briefs
Intellect offers free mental healthcare access to health workers in Singapore
Mental health startup Intellect has extended free three-month premium access to its mobile app for healthcare workers in Singapore.
CEO and co-founder Theodoric Chew said in a statement that this is their way of giving back to the “healthcare heroes” who have been swamped due to the recent surge of COVID-19 cases. This offering also comes as the company found last year that its app utilisation rate among health workers was below 1.8%.
Last month, infections in the city-state blew up due to the highly transmissible Omicron variants. As the country’s health workforce has been stretched out to provide care for patients, the Ministry of Health was led to tap the Singapore Armed Forces to fill in shortages.
Presently, the startup is still giving free premium app subscriptions to clients and partners of the non-profit group Care Corner Singapore until May. They are people living in middle and low-income communities whose mental well-being has been impacted by the ongoing pandemic.
Terumo’s US-based unit partners with Corazon to expand predictive analytics
Terumo Health Outcomes, a division of Japanese medical device maker Terumo Corporation’s US business, has entered into a collaboration and marketing deal with Corazon, a health consultant and accreditation services provider based in Pennsylvania.
The agreement involves ePRISM, a predictive analytics platform by Terumo Health Outcomes. The technology uses AI to predict unanticipated results following patients’ cardiac procedures. It supports clinicians in making treatment decisions pre-procedure to prevent complications.
Corazon, which provides consulting and accreditation services to heart, vascular, neuroscience and orthopaedic specialty programmes, said its partnership with Terumo Health Outcomes “will provide new insights that guide programmes forward in today’s ever-changing healthcare environment, particularly within the key cardiovascular service line”.
SeekIn gets CE mark for AI all-cancer detection kit
Chinese biotech company SeekIn has been cleared to market its AI-driven all-cancer screening test in Europe.
According to a press release, the SeekInCare Cancer Detection Kit runs on AI that uses insights from both public and private data to identify weak cancer DNA and protein signals in the blood and trace them back to a tissue of origin.
SeekIn noted that existing early cancer screening tests in the market cover a few cancer types, such as lung, colon, liver, breast, cervix and prostate and have limited detection rate and specificity.
Its latest blood-based diagnostic tool is able to cover multiple cancer types by employing a unique approach to capture common genomic and epigenetic features of cancer in the blood. The test can also detect various cancer types in asymptomatic patients, added CEO and founder Dr Mao Mao.
The company is still in the process of meeting additional regulatory requirements in Europe and securing approvals in China and Japan.